Shares of Madrigal Pharmaceuticals (MDGL) surged 8.24% in the pre-market trading session on Wednesday, February 26, 2025, driven by the company's promising clinical trial data for its drug Rezdiffra and better-than-expected financial results for the fourth quarter of 2024.
Madrigal reported positive two-year data from the open-label compensated MASH (metabolic dysfunction-associated steatohepatitis) cirrhosis arm of the Phase 3 MAESTRO-NAFLD-1 trial. Patients treated with Rezdiffra achieved a mean 6.7 kPa reduction in liver stiffness, the largest reported reduction in a compensated MASH cirrhosis population to date. This data reinforces the potential benefit of Rezdiffra in treating this underserved patient population with no approved therapies.
Additionally, the company reported fourth-quarter 2024 revenue of $103.3 million, exceeding analyst estimates of $99.1 million, and a narrower net loss of $2.71 per share compared to the expected loss of $4.12 per share. Madrigal ended the year with a strong cash position of $931.3 million, positioning the company for continued growth and expansion.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.